TrialBreast cancer research : BCR2021

An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer.

Erica M Stringer-Reasor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.